
Monday, March 30, 2020 1:56:10 AM
https://www.astrazeneca.com/media-centre/articles/2020/our-update-on-covid-19.html
PUBLISHED
13 March 2020
AstraZeneca is responding to the COVID-19 (novel coronavirus) outbreak, consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.
Our medicines supply chain is robust, and we continue to monitor the situation closely. Our stringent quality management system ensures the safety, quality and efficacy of all our medicines at all times.
As a science-led biopharmaceutical company, our clinical research is crucial to the development of innovative new medicines, and we have taken appropriate measures to ensure continuity and mitigate any impact to our research and development programmes.
To help protect the health and wellbeing of our 70,000 employees around the world and the communities in which we operate, we have implemented temporary measures to help reduce the risk of infection. These include leveraging digital technology to support working-from-home, as well as restricting business travel, off-site meetings and external visitors to AstraZeneca sites. Our guidance is aligned with local government authorities.
AstraZeneca is engaging with international health authorities and governments in response to the outbreak. We have provided our science and technology expertise to authorities including the World Health Organization (WHO) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Through our scientific expertise in infectious disease and proprietary antibody discovery technology, we have rapidly mobilised our research efforts to discovering novel coronavirus-neutralising antibodies as a treatment to prevent COVID-19 disease. Our teams are now focused on identifying monoclonal antibodies to progress into clinical trial evaluation. We look forward to providing more updates on our research soon.
C4urself the 1st Ammendment.
Don't assume that i don't know, and i wont assume, that you have no idea.
Recent AZNCF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/14/2025 02:30:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/01/2025 03:34:02 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/26/2025 07:00:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/24/2025 10:59:24 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/13/2025 04:03:39 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2025 02:46:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2025 01:53:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2025 05:07:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2025 04:38:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2025 04:22:35 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/10/2025 10:00:23 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2025 04:06:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2025 03:52:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2025 02:29:45 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2025 11:08:27 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/19/2025 11:59:57 AM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 02/18/2025 09:07:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/18/2025 09:01:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/18/2025 03:30:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/18/2025 01:02:37 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/18/2025 12:49:34 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/28/2025 02:25:14 PM
- Form F-6 - Registration of American Depository Receipt shares, not immediately effective • Edgar (US Regulatory) • 01/21/2025 05:17:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/21/2025 11:40:26 AM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM